Clinical Report: Impact of Chlorella vulgaris Supplementation on NAFLD Outcomes

Overview

This systematic review and meta-analysis evaluates the effects of Chlorella vulgaris supplementation on cardiovascular disease risk factors in individuals with non-alcoholic fatty liver disease (NAFLD). The findings suggest potential benefits in improving lipid profiles, glycemic control, and inflammatory markers, although further research is warranted.

Background

Non-alcoholic fatty liver disease (NAFLD) is a prevalent condition affecting a significant portion of the global population, with serious implications for liver health and cardiovascular risk. As metabolic dysfunction-associated steatotic liver disease (MASLD) gains recognition, effective interventions are critical for managing associated health risks. Nutritional supplements like Chlorella vulgaris may offer therapeutic benefits, but their efficacy in this context requires thorough investigation.

Data Highlights

No numerical data available in the provided source material.

Key Findings

• Chlorella vulgaris supplementation may improve lipid metabolism in NAFLD patients.
• It has potential benefits for insulin sensitivity and inflammatory biomarkers.
• The study utilized the GRADE framework to assess the quality of evidence.
• Randomized controlled trials (RCTs) were the primary source of data for this meta-analysis.
• Further research is needed to confirm long-term benefits and mechanisms of action.

Clinical Implications

Healthcare professionals should consider the potential role of Chlorella vulgaris as an adjunctive therapy in managing NAFLD, particularly in improving cardiovascular risk factors. However, it is essential to remain cautious and await further studies to validate these findings before widespread clinical application.

Conclusion

Chlorella vulgaris supplementation shows promise in addressing cardiovascular risk factors in NAFLD patients, but additional research is necessary to establish its long-term efficacy and safety.

References

1. Journal of Gastroenterology, 2022 -- Comprehensive Review and Meta-Analysis: Factors Affecting the Interpretation of Clinical Trial Outcomes in Non-Alcoholic Fatty Liver Disease (NAFLD)
2. Drugs - Real World Outcomes, 2021 -- Association Between Objective Clinical Measures and Patient-Reported Outcomes in Nonalcoholic Fatty Liver Disease Management with Essential Phospholipids: Insights from a Pooled Analysis of Observational Studies
3. the new gastroenterologist, 2026 -- Steroids show modest 28-day benefit in severe alcohol-associated hepatitis
4. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) - PMC
5. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA
6. Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial - PubMed
7. Obesity Surgery — Incidence of Liver Impairment Following One-Anastomosis Gastric Bypass: A Comprehensive Review and Single-Arm Meta-Analysis
8. EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) - PMC
9. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease | FDA
10. Investigation of the effects of Chlorella vulgaris supplementation in patients with non-alcoholic fatty liver disease: a randomized clinical trial - PubMed